ConductScience.org, home

Comparison · NCT01717742-ebad0ebd

Intervention vs Control: Number of Participants With Hospital Readmission

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Intervention vs Control: Number of Participants With Hospital Readmission. Trial comparisons, record NCT01717742-ebad0ebd. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01717742-ebad0ebd

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.04080.01130.137wilson
Risk in group 200.000000000000000006940.0741wilson
Risk difference, group 1 minus group 20.0408-0.0390.137newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treat, for one more participant with the outcome on Intervention than on Control24.5from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: control.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1InterventionIntervention group received intrapleural tPA, 4 mg, followed by DNase (Roche), 5 mg249OG000
Group 2ControlControl group received intrapleural tPA (Roche), 4 mg, followed by 5 mL of normal saline048OG001

Outcome

Type
SECONDARY
Title
Number of Participants With Hospital Readmission
Description
Number of Participants who had any hospital readmission after discharge from hospital for initial treatment for pleural empyema within three months related to pleural empyema or its treatment.
Time frame
3 months post-discharge
Population

Source ClinicalTrials.gov

Trial

Title
Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial)
NCT number
NCT01717742
Phases
PHASE3
Conditions
Pleural Empyema
Interventions
TPA (Tissue Plasminogen Activator), DNase, Placebo
Lead sponsor
The Hospital for Sick Children
Results first posted
2020-04-03

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01717742-ebad0ebd